Company Overview and News

38
Tracking How Far They Fell: August Service Sector Edition

2018-09-10 seekingalpha
During March and April, I wrote a series of articles that examined how far several large-cap service sector stocks might fall during a bear market.
UNP VPU CCL FDX ADBE NSC BRK.A NKE SPGI GWW MGA JNJ MG AAPL CCL PAYX

 
Moody's (MCO) Loses Appeal Against SFC's Order in Hong Kong

2018-09-04 zacks
Moody’s (MCO - Free Report) appeal against the Securities and Futures Commission’s (SFC), which regulates Hong Kong's securities and futures markets, regulatory proceedings has been dismissed by Hong Kong’s Court of Final Appeal. These proceedings relate to a report issued by the company in 2011 for which the SFC had alleged that the report violated the regulatory body’s code of conduct. Moody’s Investors Service Hong Kong Limited — the Hong Kong rating arm of Moody’s — published a report in July 2011 titled “Red Flags for Emerging-Market Companies: A Focus on China.
SPGI EFX ABM MCO

3
S&P Global Has A Rare Moat And Growth Potential

2018-08-31 seekingalpha
While most investors are familiar with S&P Global (SPGI), surprisingly few investors have this stock on their radar. This is a shame, as the stock has an extremely rare wide moat and growth potential. In this article, I will analyze why investors should put this stock on their radar.
BRK.A SPGI

 
S&P Global Inc: Strong Growth In Earnings And Free Cash Flow

2018-08-28 seekingalpha
S&P Global Inc. (SPGI) has a strong track record in growing both earnings and free cash flow.
SPGI

 
Here's Why Investors Should Hold S&P Global (SPGI) Stock Now

2018-08-27 zacks
Shares of S&P Global Inc. (SPGI - Free Report) have gained a massive 33.5% in a year’s time, outperforming the 26.5% rally of the industry it belongs to.We believe that the company has the potential to carry on with this outperformance, moving ahead.
TSS G SPGI WEX

13
Tracking How Far They Fell: July Service And Financial Sector Edition

2018-08-13 seekingalpha - 1
From March through June, I wrote a series of articles that examined how far several large-cap service and financial sector stocks might fall during a bear market.
STT UNP VPU PGR FDX CCL ROST SPYR BRK.A FISV SGLRF SPGI GWW MGA MG AAPL CCL XSPY PAYX

90
Tracking Dan Loeb's Third Point Portfolio - Q2 2018 Update

2018-08-12 seekingalpha - 7
Dan Loeb's 13F portfolio value increased from $13.32B to $14.35B this quarter. The number of positions decreased from 40 to 38.
ATHTF STZ.B TWX CRM DOW DOV MELI PBF TPRE WP KDMN STZ UTX BKI TWC PVH DVMT FPAC.U GOOGL MSFT APY MHK TPNTF GRBK FB DOV.WI LEN NXPI PYPL NFLX BAX GOOG LEN.B MPC PAGS ADBE SPGI EGN MON ICE SHY CWH EA WYNN ANTM DWDP BID BLK V DHR ANTX

 
S&P Global (SPGI) Gains From Buyouts, Weak Issuance a Concern

2018-08-11 zacks
Shares of S&P Global Inc. (SPGI - Free Report) have gained a massive 35.4% over the past year, outperforming the 25.1% rally of the industry it belongs to.
SPSC GJV SPGI NWS NWSA HSII BGSF

35
Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q2 2018 Update

2018-08-08 seekingalpha
The portfolio continues to be very concentrated with the top five positions accounting for ~29% of the 13F portfolio.
FB SERV IBKR GOOG MHFI SPGI CME AGN AMT AVGO WSH ICE FIS INTC BIDU CBRE ECL AWI EFX VRSN WLTW ZTS V 7018 CBG PRI GOOGL CACC ADI BRCM TNET

 
Dividend Aristocrat Performance: July 2018

2018-08-03 seekingalpha
Components of the S&P 500 that have paid steadily increasing dividends for at least 25 years have outperformed the broader market over time.
SYY FRT SPGI CVX MS LEG

4
S&P Global (SPGI) Surpasses Q2 Earnings & Revenue Estimates

2018-07-27 zacks
S&P Global Inc. (SPGI - Free Report) reported strong second-quarter 2018 results wherein both earnings and revenues surpassed the Zacks Consensus Estimate.
FISV SPGI CMSA EQT VRSK CMS APTV

 
S&P Global Inc. (SPGI) CEO Doug Peterson on Q2 2018 Results - Earnings Call Transcript

2018-07-26 seekingalpha
Good morning and welcome to S&P Global Second Quarter 2018 Earnings Conference Call. I'd like to inform you that this call is being recorded for broadcast. All participants are in a listen-only mode. We will open the conference to questions and answers after the presentation, and instructions will follow at that time. To access the webcast and slides, go to investor.spglobal.com, that is investor.spglobal.
SPGI

 
S&P Global (SPGI) Tops Q2 Earnings and Revenue Estimates

2018-07-26 zacks
S&P Global Inc. (SPGI - Free Report) reported second-quarter 2018 earnings per share of $2.17 (on an adjusted basis), beating the Zacks Consensus Estimate of $2.13. Earnings increased 26% on a year-over-year basis.
IBCP SPGI IBTX INDB

 
S&P Global (SPGI) Tops Q2 Earnings and Revenue Estimates

2018-07-26 zacks
S&P Global (SPGI - Free Report) just came out with quarterly earnings of $2.17 per share, beating the Zacks Consensus Estimate of $2.13 per share. This compares to earnings of $1.72 per share a year ago. These figures are adjusted for non-recurring items.
SPGI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 580645109